Pancreatic Cancer Research

ResearcherColumbia UniversityActive in the last 2 years

Susan Elaine Bates

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6708-0330; OpenAlex author ID A5013592290. Sources: ClinicalTrials.gov.

Their work

Papers
25 (first author 4, last author 9)
Trials
3 (principal investigator on 3)
Grants
1
Labs led
2
Collaborators
110
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 3 papers, 1 trial · 2018: 1 trial · 2019: 1 paper · 2020: 2 papers, 1 grant · 2021: 2 papers · 2022: 3 papers, 1 trial · 2023: 1 paper · 2024: 1 paper · 2025: 3 papers · 2026: 6 papers

Papers 25

  1. Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.drup.2025.101312↗
  2. Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives. Co-author DOI 10.1038/s41467-026-76559-4↗
  3. Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma. Last author DOI 10.1093/oncolo/oyag091↗
  4. Equipoise lost in pancreatic cancer: reimagining crossover for promising cancer therapies. First author DOI 10.1093/oncolo/oyag347↗
  5. Impact of β-Blockers, Statins, and Cholinergic Agents on Clinical Outcomes in Pancreatic Cancer: A Retrospective VA Cohort Study. Last author DOI 10.1158/1055-9965.epi-26-0062↗
  6. Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO. Co-author DOI 10.1200/po-26-00138↗
  7. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5191↗
  8. A phase 0, window of opportunity study of parasympathetic stimulation with bethanechol in localized pancreatic adenocarcinoma prior to surgery. Last author DOI 10.1093/oncolo/oyaf162↗
  9. CA19-9 as a Dynamic Biomarker for Continuous Monitoring of Therapeutic Efficacy in Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers17243902↗
  10. Beyond BRCA: Diagnosis and management of homologous recombination repair deficient pancreatic cancer. Last author DOI 10.1053/j.seminoncol.2023.11.001↗
  11. Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-Wo… Last author DOI 10.1093/oncolo/oyac217↗
  12. Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients. Co-author DOI 10.1002/cnr2.1565↗
  13. Long-term follow-up experience with adjuvant therapy after irreversible electroporation of locally advanced pancreatic cancer. Co-author DOI 10.1002/jso.27085↗
  14. Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2022.2066767↗
  15. Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain. First author DOI 10.1053/j.seminoncol.2021.01.001↗
  16. Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans. Last author DOI 10.1053/j.seminoncol.2021.02.001↗
  17. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcin… Co-author DOI 10.1200/jco.20.00590↗
  18. Prevention of Venous Thromboembolism in Pancreatic Cancer: Breaking Down a Complex Clinical Dilemma. Last author DOI 10.1634/theoncologist.2019-0264↗
  19. Neoadjuvant Treatment for Pancreatic Cancer. Last author DOI 10.1053/j.seminoncol.2018.12.002↗
  20. Pancreatic Cancer: Challenge and Inspiration. Co-author DOI 10.1158/1078-0432.ccr-16-2069↗
  21. Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma". Co-author DOI 10.1158/1078-0432.ccr-16-2070↗
  22. Clinical Trials in Pancreatic Cancer: A Long Slog. First author DOI 10.1634/theoncologist.2017-0453↗
  23. Clinical trials: New drug for pancreatic cancer highlights the dual effect of regulatory approvals. Co-author DOI 10.1038/nrclinonc.2016.22↗
  24. Targeting KRAS and the vitamin D receptor via microtubules First author DOI 10.1038/nrclinonc.2015.125↗
  25. Pancreatic cancer: steps in the right direction. Co-author DOI 10.1158/1078-0432.ccr-12-2162↗

Trials 3

  1. Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma Principal investigator NCT05241249↗
  2. Bethanechol Prior to Pancreatic Surgery Principal investigator NCT03572283↗
  3. Azacitidine and Pembrolizumab in Pancreatic Cancer Principal investigator NCT03264404↗

Grants 1

  1. Exploiting a Metabolic Vulnerability Created by Epigenetic Therapy AWARD pancan:2020-susan-bates-md-exploiting-a-metabolic-vulnerability-cre

Closest collaborators

The 25 strongest of 110 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gulam Abbas Manji · 10 shared papers, 2019–2026 · strength 1.94
  2. Tito Fojo · 7 shared papers, 2015–2026 · strength 1.23
  3. John A. Chabot · 7 shared papers, 2017–2026 · strength 1.04
  4. Ruth Aroon White · 3 shared papers, 2025–2026 · strength 0.82
  5. Michael D. Kluger · 4 shared papers, 2022–2026 · strength 0.68
  6. Beth Schrope · 4 shared papers, 2022–2026 · strength 0.68
  7. Kruti Bhagirath Vora · 1 shared paper, 2026 · strength 0.63
  8. Kenneth P. Olive · 3 shared papers, 2026 · strength 0.62
  9. Keith Magnus Sigel · 3 shared papers, 2021–2026 · strength 0.59
  10. Paul E. Oberstein · 3 shared papers, 2020–2026 · strength 0.56
  11. Celine Yeh · 3 shared papers, 2021–2023 · strength 0.54
  12. Alexander Grenander Raufi · 3 shared papers, 2019–2026 · strength 0.53
  13. Jiheum Park · 2 shared papers, 2022–2026 · strength 0.48
  14. Rachael Ann Safyan · 2 shared papers, 2023–2026 · strength 0.41
  15. Alina Cornelia Iuga · 2 shared papers, 2026 · strength 0.39
  16. Michael S. May · 2 shared papers, 2026 · strength 0.39
  17. Linda Y. Wu · 2 shared papers, 2026 · strength 0.39
  18. Benjamin Izar · 2 shared papers, 2026 · strength 0.39
  19. Eric Van Cutsem · 2 shared papers, 2020–2025 · strength 0.36
  20. Meredith LaRose · 1 shared paper, 2024 · strength 0.36
  21. Jason Cham · 1 shared paper, 2026 · strength 0.33
  22. Agnès Basseville · 2 shared papers, 2015–2026 · strength 0.32
  23. Johannes Bogers · 1 shared paper, 2025 · strength 0.28
  24. Luigi Brancato · 1 shared paper, 2025 · strength 0.28
  25. Naomi Yamamoto · 1 shared paper, 2026 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.